文献速递胸部肿瘤

一线奥希替尼治疗EGFR突变阳性且体能状态差的NSCLC患者的前瞻性II期试验(OPEN/TORG2040)

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).
PubMed 文献 · J Thorac Oncol · 2025-01-02

这项多中心II期试验纳入30例未经治疗、EGFR敏感突变且PS 2-4的晚期NSCLC患者,口服奥希替尼80mg每日一次。客观缓解率63.3%(90%CI 46.7%-77.9%;单侧p=0.033),疾病控制率93.3%,PS改善率63.3%,中位无进展生存期8.0个月、总生存期25.4个月。8例(26.7%)因严重不良事件停药,6例(20.0%)发生间质性肺病。

要点

  • PS 2-4的EGFR突变NSCLC患者一线奥希替尼客观缓解率63.3%,达到主要终点。
  • 疾病控制率93.3%,PS改善率63.3%,总体健康状况/生活质量也有改善。
  • 8例(26.7%)因严重不良事件停药,6例(20.0%)发生间质性肺病,需重视间质性肺病风险管理。

核心结论

  • 这项前瞻性研究证实了一线奥希替尼在EGFR突变阳性且PS差的NSCLC患者中的疗效,并强调需要间质性肺病风险管理。

研究设计与样本

  • 多中心II期试验(OPEN/TORG2040),纳入既往未治疗的晚期NSCLC、携带EGFR敏感突变且PS为2至4的患者。
  • 共纳入30例患者(PS 2者22例、PS 3者6例、PS 4者2例),中位年龄75岁(范围41-92岁),18例有脑转移。
  • 奥希替尼80mg每日一次口服;主要终点为客观缓解率,次要终点包括疾病控制率、PS改善率、患者报告结局和安全性。
  • 入组时间为2021年2月至2022年2月;试验注册号:日本临床试验注册库jRCTs041200100。

主要发现

  • 客观缓解率为63.3%(90%置信区间46.7%-77.9%;单侧p=0.033)。
  • 疾病控制率和PS改善率分别为93.3%和63.3%;总体健康状况/生活质量也有改善。
  • 中位无进展生存期为8.0个月,中位总生存期为25.4个月。
  • 8例(26.7%)发生导致停药的严重不良事件,6例(20.0%)发生间质性肺病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib is the first-line treatment for patients with NSCLC who have EGFR mutations and favorable performance status (PS). Despite the increasing clinical data on osimertinib, evidence for its use in patients with impaired PS remains limited. Therefore, a multicenter phase II trial (OPEN/TORG2040) was conducted to evaluate the efficacy and safety of first-line osimertinib treatment in patients with EGFR mutation-positive NSCLC and a poor PS. METHODS: Patients with previously untreated advanced NSCLC harboring EGFR-sensitizing mutations and PS of 2 to 4 were enrolled. Osimertinib (80 mg once daily) was orally administered to eligible patients. The primary end point was objective response rate. The secondary end points were disease control rate, PS improvement rate, patient-reported outcomes, and safety. RESULTS: Between February 2021 and February 2022, 30 patients with poor PS (22 with a PS of 2, six with a PS of 3, and two with a PS of 4) were enrolled. The median age was 75 (range, 41-92) years, and 18 patients had brain metastases. The objective response rate was 63.3% (90% confidence interval, 46.7%-77.9%; one-sided, p = 0.033). Disease control and PS improvement rates were 93.3% and 63.3%, respectively. Global health status/QoL also improved. Median progression-free and overall survival were 8.0 and 25.4 months, respectively. Eight patients (26.7%) experienced serious adverse events leading to discontinuation, and six (20.0%) experienced interstitial lung disease. CONCLUSIONS: This prospective study confirmed the efficacy of first-line osimertinib treatment in patients with EGFR mutation-positive NSCLC and poor PS, highlighting the need for interstitial lung disease risk management. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials Identifier: jRCTs041200100.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Fukui T, Mamesaya N, Takahashi T, et al. A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040). J Thorac Oncol. 2025. PMID: 39755169. doi:10.1016/j.jtho.2024.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。